Eli Lilly and Company or Jazz Pharmaceuticals plc: Who Invests More in Innovation?

Eli Lilly vs. Jazz: A Decade of R&D Investment

__timestampEli Lilly and CompanyJazz Pharmaceuticals plc
Wednesday, January 1, 2014473360000085181000
Thursday, January 1, 20154796400000135253000
Friday, January 1, 20165243900000162297000
Sunday, January 1, 20175281800000198442000
Monday, January 1, 20185051200000226616000
Tuesday, January 1, 20195595000000299726000
Wednesday, January 1, 20206085700000335375000
Friday, January 1, 20217025900000505748000
Saturday, January 1, 20227190800000590453000
Sunday, January 1, 20239313400000849658000
Monday, January 1, 202414271000000
Loading chart...

Unleashing the power of data

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Eli Lilly and Company and Jazz Pharmaceuticals plc are two giants in this arena, each with a distinct approach to research and development (R&D) investment. Over the past decade, Eli Lilly has consistently outpaced Jazz Pharmaceuticals, investing nearly 18 times more in R&D by 2023. Starting from 2014, Eli Lilly's R&D expenses have surged by approximately 97%, reaching a peak in 2023. In contrast, Jazz Pharmaceuticals has shown a steady, albeit smaller, increase of around 900% in the same period. This stark difference highlights Eli Lilly's aggressive strategy to lead in pharmaceutical innovation. As the industry evolves, these investments could be pivotal in determining which company will spearhead the next wave of medical breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025